Document Detail

Do erythropoietic-stimulating agents relieve fatigue? A review of reviews.
MedLine Citation:
PMID:  21052957     Owner:  NLM     Status:  In-Process    
Interest in the efficacy and potential deleterious consequences of treatment with erythropoietic-stimulating agents (ESAs) is very high. Recently, the ESAs have come under intense scrutiny as several clinical trials have shown their use to be associated with an increased risk of thrombosis, and a concern for increased mortality risk in oncology. In this context, attention to the effect of ESAs upon fatigue and other aspects of quality of life has tended to be lost. To aid inclusion of this endpoint in the important consideration of risks and benefits of ESA therapy, we summarize the many reviews that have been conducted on this topic. The ten selected reviews were all conducted systematically or were otherwise comprehensive. While these reviews acknowledge an overall positive fatigue or quality-of-life effect, some were equivocal about the meaningfulness or magnitude of the benefit. The overall evidence from these reviews supports a fatigue and overall quality-of-life benefit from treatment with ESAs that is unlikely to be due to chance. This information should be included in the risk/benefit consideration of these controversial agents.
David T Eton; David Cella
Related Documents :
19293757 - Ejprm systematic continuous update on cochrane reviews in rehabilitation: news from the...
16105487 - Evaluation of syncope.
18368407 - Polyarteritis nodosa presenting as pancytopenia: case report and review of the literature.
1335357 - Calcitriol: a hematolymphopoietrope?
16832837 - Klippel-trenaunay-weber syndrome involving fetal thigh: prenatal presentations and outc...
24618057 - Locally destructive mandibular pseudotumor as a manifestation of immunoglobulin g4-rela...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer treatment and research     Volume:  157     ISSN:  0927-3042     ISO Abbreviation:  Cancer Treat. Res.     Publication Date:  2011  
Date Detail:
Created Date:  2010-11-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8008541     Medline TA:  Cancer Treat Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  181-94     Citation Subset:  IM    
Department of Health Sciences Research, Division of Healthcare Policy & Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy...
Next Document:  Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.